John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 11,700 shares at $193.84 ($2.2M) on 2021-05-03, disclosed to the SEC on 2021-05-05.
Open-market sale of $2.2M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $189.25 | 600 | $114K | 5.1% |
| 2 | $190.53 | 1,320 | $252K | 11.2% |
| 3 | $190.53 | 1,320 | $251K | 11.2% |
| 4 | $191.83 | 2,880 | $552K | 24.6% |
| 5 | $191.83 | 2,880 | $552K | 24.6% |
| 6 | $192.54 | 2,200 |
| $424K |
| 18.9% |
| 7 | $193.84 | 300 | $58K | 2.6% |
| 8 | $194.90 | 100 | $19K | 0.9% |
| 9 | $198.09 | 100 | $20K | 0.9% |
| Total | $191.67 avg | 11,700 | $2.2M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |